½ÃÀ庸°í¼­
»óǰÄÚµå
1753945

Á¤Çü¿Ü°ú ¿¬ºÎÁ¶Á÷ ¼öº¹ ½ÃÀå º¸°í¼­ : ½Ã¼úº°, ¼Õ»ó ºÎÀ§º°, ÃÖÁ¾»ç¿ëÀÚº°, Áö¿ªº°(2025-2033³â)

Orthopedic Soft Tissue Repair Market Report by Procedure, Injury Location, End User, and Region 2025-2033

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: IMARC | ÆäÀÌÁö Á¤º¸: ¿µ¹® 144 Pages | ¹è¼Û¾È³» : 2-3ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

¼¼°è Á¤Çü¿Ü°ú ¿¬ºÎÁ¶Á÷ ¼öº¹ ½ÃÀå ±Ô¸ð´Â 2024³â 38¾ï ´Þ·¯¿¡ ´ÞÇß½À´Ï´Ù. ÇâÈÄ IMARC GroupÀº 2033³â¿¡´Â 54¾ï ´Þ·¯¿¡ µµ´ÞÇÏ¿© 2025-2033³â µ¿¾È 3.94%ÀÇ ¿¬Æò±Õ ¼ºÀå·ü(CAGR)À» º¸ÀÏ °ÍÀ¸·Î ¿¹ÃøÇϰí ÀÖ½À´Ï´Ù. ³ëÀÎ Àα¸ÀÇ Áõ°¡, ÀÇ·á ºÎ¹®ÀÇ Áö¼ÓÀûÀÎ ±â¼ú ¹ßÀü, ½ºÆ÷Ã÷ Ȱµ¿ Âü¿©ÀÚ Áõ°¡ µîÀÌ ½ÃÀå ¼ºÀåÀ» À̲ô´Â ÁÖ¿ä ¿äÀÎÀ¸·Î ²ÅÈü´Ï´Ù.

Á¤Çü¿Ü°ú ¿¬ºÎÁ¶Á÷ ¼öº¹ ½ÃÀå ºÐ¼®

  • ÁÖ¿ä ½ÃÀå ÃËÁø¿äÀÎ : ÇÁ·Î ½ºÆ÷Ã÷¿¡ ÁøÃâÇÏ´Â ±â¾÷ÀÌ Áõ°¡ÇÔ¿¡ µû¶ó ½ºÆ÷Ã÷ °ü·Ã ºÎ»óÀÇ À§ÇèÀÌ Å©°Ô Áõ°¡Çϰí ÀÖÀ¸¸ç, ÀÌ´Â Á¤Çü¿Ü°ú ¿¬ºÎÁ¶Á÷ º¹±¸ ½ÃÀåÀÇ ¼ö¿ä¸¦ ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, Á¤Çü¿Ü°ú ÀÎ´ë ÆÄ¿­·Î ÀÎÇÑ º¹ÀâÇÑ ½Å°æ±ÙÅë °ü¸®¿¡ È¿°úÀûÀÎ Ç÷¼ÒÆÇdzºÎÇ÷Àå°ú °°Àº »õ·Î¿î Ä¡·á¹ýÀÇ µµÀÔÀÌ »ê¾÷ÀÇ ¼ºÀåÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù.
  • ÁÖ¿ä ½ÃÀå µ¿Çâ : ¹ÙÀÌ¿ÀÇÁ¸°ÆÃ, ¹ÙÀÌ¿À¸Þ½Ã, ¹ÙÀÌ¿ÀÆÐºê¸®ÄÉÀÌ¼Ç µî ÷´Ü ±â¼úÀÇ º¸±ÞÀÌ È®´ëµÇ¸é¼­ Á¤Çü¿Ü°ú ¿¬ºÎÁ¶Á÷ ¼öº¹¹° ½ÃÀåÀÇ ¼ö¿ä°¡ È®´ëµÉ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¶ÇÇÑ, ±¤¹üÀ§ÇÑ ¿¬±¸°³¹ß(R&D) Ȱµ¿, »õ·Î¿î ±â±â ¹× Ä¡·á¹ý Çõ½Å, 1Àδç ÀÇ·áºñ ÁöÃâ Áõ°¡µµ ½ÃÀå ¼ºÀå¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù.
  • °æÀï »óȲ : Á¤Çü¿Ü°ú ¿¬ºÎÁ¶Á÷ º¹±¸ ½ÃÀåÀÇ ÁÖ¿ä ±â¾÷À¸·Î´Â Arthrex Inc. Johnson & Johnson,LifeNet Health,MTF Biologics,Smith & Nephew plc,Stryker Corporation,Tissue Regenix Group plc,Zimmer Biomet µîÀÌ ÀÖ½À´Ï´Ù.
  • Áö¸®Àû µ¿Çâ : ºÏ¹Ì¿Í À¯·´ÀÌ Á¤Çü¿Ü°ú ¿¬ºÎÁ¶Á÷ º¹¿ø ½ÃÀå¿¡¼­ Å« ºñÁßÀ» Â÷ÁöÇϰí ÀÖ½À´Ï´Ù. °í·ÉÈ­ Àα¸, ³ôÀº ½ºÆ÷Ã÷ °ü·Ã ºÎ»ó À¯º´·ü, ¼±ÁøÈ­µÈ ÀÇ·á ÀÎÇÁ¶ó, ¿ì¼öÇÑ »óȯ Á¦µµ µî ´Ù¾çÇÑ ¿äÀÎÀÌ ÀÌ Áö¿ªÀÇ ½ÃÀå ¼ºÀå¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ¾Æ½Ã¾ÆÅÂÆò¾ç¿¡¼­´Â ÀÇ·á ÀÎÇÁ¶ó °³¼±, °¡Ã³ºÐ ¼Òµæ Áõ°¡, ÷´Ü Ä¡·á ¿É¼Ç¿¡ ´ëÇÑ ÀÎ½Ä Áõ°¡°¡ ½ÃÀå ¼ºÀåÀÇ ¿øµ¿·ÂÀÌ µÇ°í ÀÖ½À´Ï´Ù.
  • µµÀü°ú ±âȸ : ¿¬ºÎÁ¶Á÷ ½Ã¼úÀÇ ºñ¿ë ¾ïÁ¦, ±ÔÁ¦Àû Àå¾Ö¹°, ±â¼úÀÇ º¹À⼺, ÁÖ¿ä ±â¾÷ °£ÀÇ °æÀï ½ÉÈ­ µîÀÌ ½ÃÀåÀÌ Á÷¸éÇÑ ÁÖ¿ä °úÁ¦ÀÔ´Ï´Ù. ±×·¯³ª Áö¼ÓÀûÀÎ ¿¬±¸°³¹ß ³ë·ÂÀ¸·Î ¿¬ºÎÁ¶Á÷ ¼öº¹À» À§ÇÑ Çõ½ÅÀûÀÎ ±â¼ú ¹× »ýüÀç·á°¡ °³¹ßµÇ¾î ½Ã¼ú °á°ú¿Í ȯÀÚÀÇ È¸º¹ ½Ã°£À» °³¼±Çϰí ÀÖÀ¸¸ç, ÀÌ¿¡ ´ëÇÑ »ê¾÷ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù.

Á¤Çü¿Ü°ú ¿¬ºÎÁ¶Á÷ ¼öº¹ ½ÃÀå µ¿Çâ

Á¤Çü¿Ü°úÀû ¼Õ»óÀÇ Áõ°¡

Á¤Çü¿Ü°úÀû ¼Õ»óÀÇ Áõ°¡´Â Á¤Çü¿Ü°úÀû ¿¬ºÎÁ¶Á÷ º¹±¸ ½ÃÀåÀ» Å©°Ô ¹ßÀü½Ã۰í ÀÖ½À´Ï´Ù. National Athletic Trainers' Association¿¡ µû¸£¸é, 2022³â ¹Ì±¹¿¡¼­´Â ¾à 3,000¸¸ ¸íÀÇ À¯¾Æ°¡ Á¶Á÷È­µÈ ½ºÆ÷Ã÷¿¡ Âü¿©ÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, ÀÌ ¼öÄ¡´Â û¼Ò³â ½ºÆ÷Ã÷ ¸®±×ÀÇ ÀαⰡ ³ô¾ÆÁü¿¡ µû¶ó ½Ã°£ÀÌ Áö³²¿¡ µû¶ó Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ÀÌ ¼öÄ¡´Â û¼Ò³â ½ºÆ÷Ã÷ ¸®±×ÀÇ ÀαⰡ ³ô¾ÆÁü¿¡ µû¶ó ½Ã°£ÀÌ Áö³²¿¡ µû¶ó Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ÀÌ´Â ½ºÆ÷Ã÷ ºÎ»óÀÇ ¼ö¸¦ ´õ¿í Áõ°¡½Ã۰í ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, ¹Ì±¹ Áúº´¿¹¹æÅëÁ¦¼¾ÅÍ(CDC)°¡ ¹ßÇ¥ÇÑ º¸°í¼­¿¡ µû¸£¸é ¹Ì±¹¿¡¼­´Â ¸Å³â 350¸¸ ¸í ÀÌ»óÀÇ ½ºÆ÷Ã÷ °ü·Ã ºÎ»óÀÌ ¹ß»ýÇÕ´Ï´Ù. ÀÌ ¿Ü¿¡µµ 2022³â ij³ª´Ù¿¡¼­ ½Ç½ÃµÈ Á¶»ç¿¡ µû¸£¸é ij³ª´ÙÀÇ °íµîÇб³¿¡¼­ Á¢ÃË ½ºÆ÷Ã÷ Âü¿©ÀÚ Áß »ó´ç¼ö°¡ ºÎ»óÀ» ´çÇÏ´Â °ÍÀ¸·Î ³ªÅ¸³µ½À´Ï´Ù. ÀÌ Á¶»ç¿¡¼­ ºÎ»ó·üÀº ·°ºñÀÇ °æ¿ì ¿¬°£ Âü°¡ÀÚ 100¸í´ç 12.7¸í, ¾ÆÀ̽ºÇÏŰÀÇ °æ¿ì ¿¬°£ Âü°¡ÀÚ 100¸í´ç 33.1¸íÀ¸·Î ´Ù¾çÇÏ´Ù´Â °ÍÀ» ¾Ë ¼ö ÀÖ½À´Ï´Ù. ¸Ó¸® ¿Ü»ó À¯º´·üÀº 33.3%, ¼Õ¸ñ ¶Ç´Â ¼Õ ºÎ»óÀº 16.0%, ¾î±ú ºÎ»óÀº 12.8%, ¹«¸­ ºÎ»óÀº 12.0%·Î ³ªÅ¸³µ½À´Ï´Ù. ÀÌ´Â °æ¹ÌÇÑ ºÎ»ó°ú ½É°¢ÇÑ ºÎ»óÀ» ¸ðµÎ Æ÷ÇÔÇÕ´Ï´Ù. ½Åü Ȱµ¿°ú ½ºÆ÷Ã÷ Ȱµ¿ÀÌ Áõ°¡ÇÔ¿¡ µû¶ó ¿¬ºÎ Á¶Á÷ ¼Õ»óÀ» ÀÔÀ» °¡´É¼ºÀÌ ³ô¾ÆÁý´Ï´Ù. ÀÌ·¯ÇÑ ¼Õ»óÀº ÀÎ´ë ÆÄ¿­¿¡¼­ ÈûÁÙ ÆÄ¿­¿¡ À̸£±â±îÁö ´Ù¾çÇÏ¸ç ¼ö¸®¸¦ À§ÇØ ¿Ü°úÀû °³ÀÔÀÌ ÇÊ¿äÇÕ´Ï´Ù. À̿ʹ º°µµ·Î Àα¸ °í·ÉÈ­¿Í °ñ°üÀý¿°°ú °°Àº ¸¸¼ºÁúȯÀÇ À¯º´·ü Áõ°¡·Î ÀÎÇØ ¿¬ºÎÁ¶Á÷ ¼ö¸®¸¦ Æ÷ÇÔÇÑ Á¤Çü¿Ü°úÀû °³ÀÔ¿¡ ´ëÇÑ ¼ö¿äµµ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, Cleveland ClinicÀÌ ¹ßÇ¥ÇÑ ³í¹®¿¡ µû¸£¸é 55¼¼ ÀÌ»ó ¼ºÀÎÀÇ 80% ÀÌ»óÀÌ °ñ°üÀý¿°À» ¾Î°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, Á¤Çü¿Ü°úÀû °Ç°­ÀÇ Á߿伺¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁö°í ÀÇÇÐ Áö½ÄÀÌ ¹ßÀüÇÔ¿¡ µû¶ó Á¤Çü¿Ü°úÀû ¼Õ»óÀ» Ä¡·áÇÏ·Á´Â »ç¶÷µéÀÌ ´Ã¾î³ª¸é¼­ ¿¬ºÎÁ¶Á÷ º¹±¸ ½Ã¼ú¿¡ ´ëÇÑ ¼ö¿ä¸¦ °ßÀÎÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¿äÀεéÀº Á¤Çü¿Ü°ú ¿¬ºÎÁ¶Á÷ ½ÃÀåÀÇ ¼öÀͼºÀ» ³ôÀ̰í ÀÖ½À´Ï´Ù.

°í·ÉÀÚ¿Í ºñ¸¸À² Áõ°¡

°í·ÉÈ­ Àα¸ÀÇ Áõ°¡¿Í ¸¸¼ºÁúȯÀÇ ¹ß»ýÀº ¿¬ºÎÁ¶Á÷ º¹±¸ ½ÃÀåÀ» Å©°Ô °ßÀÎÇϰí ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, ¼¼°èº¸°Ç±â±¸(WHO)¿¡ µû¸£¸é 2030³â±îÁö Àü ¼¼°è Àα¸ 6¸í Áß 1¸íÀÌ 60¼¼ ÀÌ»óÀÌ µÉ °ÍÀ̶ó°í ÇÕ´Ï´Ù. À̶§ 60¼¼ ÀÌ»ó Àα¸ ºñÀ²Àº 2020³â 10¾ï ¸í¿¡¼­ 14¾ï ¸íÀ¸·Î Áõ°¡ÇÒ °ÍÀ̸ç, 2050³â¿¡´Â ¼¼°è 60¼¼ ÀÌ»ó Àα¸°¡ µÎ ¹è(21¾ï ¸í)·Î Áõ°¡ÇÒ °ÍÀ̸ç, 80¼¼ ÀÌ»ó Àα¸´Â 2020-2050³â »çÀÌ¿¡ 3¹è Áõ°¡ÇÏ¿© 4¾ï 2,600¸¸ ¸í¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ºñ¸¸À²ÀÇ ±Þ°ÝÇÑ Áõ°¡´Â ´ç´¢º´, ½ÉÇ÷°ü ¹× ½ÅÀå °ü·Ã Áúȯ°ú °°Àº ¸¸¼ºÁúȯÀÇ Áõ°¡·Î À̾îÁö°í ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, 2023³â ¼¼°èº¸°Ç±â±¸(WHO)°¡ ¹ßÇ¥ÇÑ º¸°í¼­¿¡ µû¸£¸é 2014³â 18¼¼ ÀÌ»ó ¼ºÀÎÀÇ 8.5%°¡ ´ç´¢º´À» ¾Î°í ÀÖÀ¸¸ç, 2019³â¿¡´Â ´ç´¢º´ÀÌ 150¸¸ ¸í »ç¸ÁÀÇ Á÷Á¢ÀûÀÎ ¿øÀÎÀÌ µÇ¾ú°í, 48%´Â 70¼¼ ÀÌÇÏ¿¡¼­ ¹ß»ýÇÏ¿´½À´Ï´Ù. ´ç´¢º´Àº ½ÅÀå ÁúȯÀ¸·Î ÀÎÇÑ »ç¸ÁÀÚ 460¸¸ ¸í, °íÇ÷´çÀº ½ÉÇ÷°üÁúȯÀ¸·Î ÀÎÇÑ »ç¸ÁÀÇ ¾à 20%¸¦ Â÷ÁöÇßÀ¸¸ç, 2000³âºÎÅÍ 2019³â±îÁö ¿¬·É Ç¥ÁØÈ­ ´ç´¢º´ »ç¸Á·üÀº 3% Áõ°¡Çß½À´Ï´Ù. ´ç´¢º´ °ü·Ã »ç¸Á·üÀº ÁßÀú¼Òµæ ±¹°¡¿¡¼­ 13% Áõ°¡Çß½À´Ï´Ù. ¶ÇÇÑ ¹Ì±¹ Á¤Çü¿Ü°ú ÇÐȸ°¡ ¹ßÇ¥ÇÑ ³í¹®¿¡ µû¸£¸é, ºñ¸¸Àº ÀϹÝÀûÀ¸·Î ¿¬ºÎÁ¶Á÷ÀÇ ¼Õ»ó°ú °üÀýÀÇ ÅðÇ༺ ¸¶¸ð »óÅÂÀÎ °ñ°üÀý¿°°ú °ü·ÃÀÌ ÀÖ½À´Ï´Ù. ºñ¸¸Àº °í°üÀý°ú ½½°üÀýÀÇ °ñ°üÀý¿°¿¡ Å« ¿µÇâÀ» ¹ÌĨ´Ï´Ù. üÁß 1ÆÄ¿îµå´ç 4-6ÆÄ¿îµåÀÇ ¾Ð·ÂÀÌ ½½°üÀý¿¡ °¡ÇØÁö´Â °ÍÀ¸·Î ¾Ë·ÁÁ® ÀÖ½À´Ï´Ù. ºñ¸¸ÇÑ »ç¶÷ÀÌ ¹«¸­ Àΰø°üÀý ġȯ¼úÀ» ¹Þ¾Æ¾ß ÇÒ È®·üÀº ±×·¸Áö ¾ÊÀº »ç¶÷¿¡ ºñÇØ 20¹è³ª ´õ ³ô½À´Ï´Ù. ÀÌ·¯ÇÑ ¿äÀεéÀÌ Á¤Çü¿Ü°ú ¿¬ºÎÁ¶Á÷ º¹±¸ ½ÃÀåÀÇ Á¡À¯À²À» ´õ¿í ³ôÀ̰í ÀÖ½À´Ï´Ù.

±â¼ú ¹ßÀü

±â¼ú ¹ßÀüÀº Á¤Çü¿Ü°ú ¿¬ºÎÁ¶Á÷ º¹±¸ ½ÃÀåÀÇ ¼ºÀåÀ» ÃËÁøÇÏ´Â µ¥ Áß¿äÇÑ ¿ªÇÒÀ» Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¹ßÀüÀº º¸´Ù È¿°úÀûÀÌ°í ´ú ħ½ÀÀûÀÎ Ä¡·á¹ý °³¹ß¿¡ ±â¿©ÇÏ¿© ȯÀÚÀÇ ¿¹Èĸ¦ °³¼±Çϰí ȸº¹ ½Ã°£À» ´ÜÃàÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. ¶ÇÇÑ, ±â¼ú Çõ½ÅÀ¸·Î °üÀý°æ ¹× º¹°­°æ°ú °°Àº ÃÖ¼Òħ½À ¼ö¼ú ±â¹ýÀÌ °³¹ßµÇ¾î ±âÁ¸ °³º¹ ¼ö¼ú¿¡ ºñÇØ ÁÖº¯ Á¶Á÷¿¡ ´ëÇÑ ¿Ü»óÀ» ÁÙÀ̰í, ÈäÅ͸¦ ÃÖ¼ÒÈ­Çϸç, ȸº¹ ½Ã°£À» ´ÜÃàÇϰí ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, 2023³â 7¿ù ¼¼°è ÀÇ·á ±â¼ú ±â¾÷ Smith+Nephew´Â Àεµ¿¡¼­ REGENETEN »ýüÀ¯µµ ÀÓÇöõÆ®¸¦ Ãâ½ÃÇßÀ¸¸ç, ÀÌ ÀÓÇöõÆ®´Â ¿Ü°ú Àǻ簡 ÈûÁÙÆÇ ¼ö¼ú¿¡ Á¢±ÙÇÏ´Â ¹æ½ÄÀ» º¯È­½ÃÄ×°í, Ãâ½Ã ÀÌÈÄ Àü ¼¼°èÀûÀ¸·Î 10¸¸ °Ç ÀÌ»óÀÇ ¼ö¼úÀÌ ÁøÇàµÇ¾ú½À´Ï´Ù. ½ÃÇàµÇ¾ú½À´Ï´Ù. Äݶó°Õ ±â¹ÝÀÇ ¸®Á¦³×ÅÙ »ýü À¯µµ ÀÓÇöõÆ®´Â ½ÅüÀÇ ÀÚ¿¬ Ä¡À¯ ¹ÝÀÀÀ» ÀÚ±ØÇÏ¿© »õ·Î¿î ÈûÁÙ°ú °°Àº Á¶Á÷ÀÌ »ý¼ºµÇµµ·ÏÇÔÀ¸·Î½á ÇöÀçÀÇ ÈûÁÙÀ» ÀÚ¿¬½º·´°Ô °­È­ÇÏ¿© Áúº´ÀÇ ÁøÇàÀ» º¯È­½Ãŵ´Ï´Ù. ¿ìÇ¥¸¸ÇÑ Å©±âÀÇ ÀÌ ÀÓÇöõÆ®´Â °ÇÆÇ°Ç ¼Õ»ó ºÎÀ§¿¡ ÀÛÀº Àý°³¸¦ ÅëÇØ °üÀý°æÀ¸·Î Åõ¿©µË´Ï´Ù. À̿ʹ º°µµ·Î ÁÖ¿ä ¾÷üµéÀÇ ´Ù¾çÇÑ °³¹ßµµ Á¶Á÷ º¹±¸¿¡ ´ëÇÑ ¼ö¿ä¸¦ Áõ°¡½Ã۰í ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, 2021³â 8¿ù Orthopaedic Implant Company´Â FDA ½ÂÀÎÀ» ¹ÞÀº DRPX ¼Õ¸ñ °ñÀý Ç÷¹ÀÌÆ®¸¦ ¹ßÇ¥Çß½À´Ï´Ù. ÀÌ Ç÷¹ÀÌÆ®´Â Type II ¾ç±Ø»êÈ­ ƼŸ´½°ú ¿¬ºÎÁ¶Á÷ÀÇ Ãæ°ÝÀ» ¿ÏÈ­ÇÏ´Â ¾ãÀº Ç÷¹ÀÌÆ®¿Í ½ºÅ©·ù µðÀÚÀÎÀÌ Æ¯Â¡ÀÔ´Ï´Ù. ÀÌ·¯ÇÑ ¿äÀεéÀº Á¤Çü¿Ü°ú ¿¬ºÎÁ¶Á÷ ¼öº¹¹° ½ÃÀå ¿¹Ãø¿¡ ±àÁ¤ÀûÀÎ ¿µÇâÀ» ¹ÌÄ¡°í ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå Á¶»ç ¹üÀ§¿Í Á¶»ç ¹æ¹ý

  • Á¶»ç ¸ñÀû
  • ÀÌÇØ°ü°èÀÚ
  • µ¥ÀÌÅÍ ¼Ò½º
    • 1Â÷ Á¤º¸
    • 2Â÷ Á¤º¸
  • ½ÃÀå ÃßÁ¤
    • »óÇâ½Ä Á¢±Ù
    • ÇÏÇâ½Ä Á¢±Ù
  • Á¶»ç ¹æ¹ý

Á¦3Àå ÁÖ¿ä ¿ä¾à

Á¦4Àå ¼Ò°³

  • °³¿ä
  • ÁÖ¿ä »ê¾÷ µ¿Çâ

Á¦5Àå ¼¼°èÀÇ Á¤Çü¿Ü°ú ¿¬ºÎÁ¶Á÷ ¼öº¹ ½ÃÀå

  • ½ÃÀå °³¿ä
  • ½ÃÀå ½ÇÀû
  • COVID-19ÀÇ ¿µÇâ
  • ½ÃÀå ¿¹Ãø

Á¦6Àå ½ÃÀå ³»¿ª : ½Ã¼úº°

  • ½ÊÀÚÀÎ´ë ¼öº¹
  • ¼±È¸°ÇÆÇ¼öº¹
  • »ó¿Ï°ñ ¿ÜÃø»ó°ú¿°
  • ¾ÆÅ³·¹½º°Ç¿° ¼öº¹
  • °ñ¹ÝÀå±âÅ»Ãâ
  • Á¼®±Ù°Ç ¼öº¹
  • °í°üÀý°æ °Ë»ç
  • »ó¿ÏÀÌµÎ±Ù°Ç °íÁ¤¼ú
  • ±âŸ

Á¦7Àå ½ÃÀå ³»¿ª : ºÎ»ó ºÎÀ§º°

  • ½½°üÀý
  • °ß°üÀý
  • °í°üÀý
  • ¼Ò°üÀý

Á¦8Àå ½ÃÀå ³»¿ª : ÃÖÁ¾»ç¿ëÀÚº°

  • º´¿ø
  • ¿Ü·¡ ¼¾ÅÍ
  • Á¤Çü¿Ü°ú Ŭ¸®´Ð

Á¦9Àå ½ÃÀå ³»¿ª : Áö¿ªº°

  • ºÏ¹Ì
    • ¹Ì±¹
    • ij³ª´Ù
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • Áß±¹
    • ÀϺ»
    • Àεµ
    • Çѱ¹
    • È£ÁÖ
    • Àεµ³×½Ã¾Æ
    • ±âŸ
  • À¯·´
    • µ¶ÀÏ
    • ÇÁ¶û½º
    • ¿µ±¹
    • ÀÌÅ»¸®¾Æ
    • ½ºÆäÀÎ
    • ·¯½Ã¾Æ
    • ±âŸ
  • ¶óƾ¾Æ¸Þ¸®Ä«
    • ºê¶óÁú
    • ¸ß½ÃÄÚ
    • ±âŸ
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
    • ½ÃÀå ³»¿ª : ±¹°¡º°

Á¦10Àå SWOT ºÐ¼®

  • °³¿ä
  • °­Á¡
  • ¾àÁ¡
  • ±âȸ
  • À§Çù

Á¦11Àå ¹ë·ùüÀÎ ºÐ¼®

Á¦12Àå Porter's Five Forces ºÐ¼®

  • °³¿ä
  • ±¸¸ÅÀÚÀÇ ±³¼··Â
  • °ø±Þ ±â¾÷ÀÇ ±³¼··Â
  • °æÀï Á¤µµ
  • ½Å±Ô Âü¿©¾÷üÀÇ À§Çù
  • ´ëüǰÀÇ À§Çù

Á¦13Àå °¡°Ý ºÐ¼®

Á¦14Àå °æÀï ±¸µµ

  • ½ÃÀå ±¸Á¶
  • ÁÖ¿ä ±â¾÷
  • ÁÖ¿ä ±â¾÷ °³¿ä
    • Arthrex Inc.
    • Becton Dickinson and Company
    • Boston Scientific Corporation
    • CONMED Corporation
    • Integra LifeSciences
    • Johnson & Johnson
    • LifeNet Health
    • MTF Biologics
    • Smith & Nephew plc
    • Stryker Corporation
    • Tissue Regenix Group plc
    • Zimmer Biomet
ksm

The global orthopedic soft tissue repair market size reached USD 3.8 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 5.4 Billion by 2033, exhibiting a growth rate (CAGR) of 3.94% during 2025-2033. The rising geriatric population, continuous technological advancements in the medical sector, growing participation in sports activities, etc., are some of the major factors propelling the market growth.

Orthopedic Soft Tissue Repair Market Analysis:

  • Major Market Drivers: The growing participation of individuals in professional sports has significantly increased the risks of sports-related injuries, which, in turn, is facilitating the orthopedic soft tissue repair market demand. Moreover, the introduction of new therapies, such as platelet-rich plasma, that are effective in managing complex neuromuscular pain caused due to orthopedic ligament tears is proliferating the industry's growth.
  • Key Market Trends: The increasing penetration of advanced technologies, including bioprinting, biological meshes, and bio-fabrication is anticipated to proliferate the orthopedic soft tissue repair market demand. In addition, extensive research and development (R&D) activities, innovations in new devices and therapies, and increasing healthcare per capita expenditure, are also contributing to the market growth.
  • Competitive Landscape: Some of the leading orthopedic soft tissue repair market companies are Arthrex Inc., Becton Dickinson and Company, Boston Scientific Corporation, CONMED Corporation, Integra LifeSciences, Johnson & Johnson, LifeNet Health, MTF Biologics, Smith & Nephew plc, Stryker Corporation, Tissue Regenix Group plc, and Zimmer Biomet, among others.
  • Geographical Trends: The North America and Europe markets hold prominent shares of the orthopedic soft tissue repair market. Numerous factors, such as a large aging population, high prevalence of sports-related injuries, advanced healthcare infrastructure, and robust reimbursement systems, contribute to the market growth in these regions. Moreover, in the Asia Pacific region, improving healthcare infrastructures, rising disposable incomes, and growing awareness of advanced treatment options drive the market expansion.
  • Challenges and Opportunities: Cost containment of soft tissue procedures, regulatory hurdles, technological complexity, and high competition among key players are some of the major challenges that the market is facing. However, ongoing research and development efforts lead to the development of innovative technologies and biomaterials for soft tissue repair, improving procedural outcomes and patient recovery times, thereby escalating the industry demand.

Orthopedic Soft Tissue Repair Market Trends:

Rising Incidences of Orthopedic Injuries

The increasing occurrence of orthopedic injuries is significantly propelling the orthopedic soft tissue repair market forward. Rising participation in physical activities and sports is leading to a rise in the incidence of orthopedic injuries. According to the National Athletic Trainers' Association, around 30 million children participated in organized sports in the United States in 2022. This figure has risen over time, as youth sports leagues have grown in popularity. This is further escalating the number of sports injuries. For instance, according to an article published by the Centers for Disease Control and Prevention (CDC), over 3.5 million sports-related injuries occur each year in the United States. In addition to this, a study conducted in Canada in 2022 revealed a significant percentage of injuries among contact sports participants in Canadian high schools. The survey also found that injury rates varied from 12.7 per 100 participants per year in rugby to 33.1 per 100 participants per year in ice hockey. The prevalence rate of head injuries was 33.3%; wrist or hand injuries were 16.0%; shoulder injuries were 12.8%; and knee injuries were 12.0%. This covers both minor and catastrophic injuries. As people engage in more physical activities and sports, the likelihood of sustaining soft tissue injuries rises. These injuries can range from ligament tears to tendon ruptures, requiring surgical intervention for repair. Apart from this, the aging population, coupled with a higher prevalence of chronic conditions such as osteoarthritis, also drives the demand for orthopedic interventions, including soft tissue repair. For instance, according to an article published by the Cleveland Clinic, more than 80% of adults older than 55 had osteoarthritis. Furthermore, with growing awareness about the importance of orthopedic health and advancements in medical knowledge, more people are seeking treatment for orthopedic injuries, driving the demand for soft tissue repair procedures. These factors are bolstering the orthopedic soft tissue market revenue.

Escalating Geriatric Population and Obesity Rates

The rise in the aging population and chronic disease occurrences is significantly driving the soft tissue repair market. For instance, according to the World Health Organization, by 2030, one in every six persons in the world will be 60 or older. At this time, the proportion of the population aged 60 and up would rise from 1 billion in 2020 to 1.4 billion. By 2050, the global population of people aged 60 and up would double (2.1 billion). The number of people aged 80 and older was anticipated to treble between 2020 and 2050, reaching 426 million. The significant rise in obesity rates is leading to the increasing incidence of chronic diseases such as diabetes, and cardiovascular and kidney-related illnesses. For instance, according to a report published by the World Health Organization in 2023, in 2014, 8.5% of adults aged 18 and up had diabetes. In 2019, diabetes was the direct cause of 1.5 million fatalities, with 48% occurring before the age of 70. Diabetes caused an additional 460,000 renal disease deaths, and high blood glucose was responsible for approximately 20% of cardiovascular fatalities. Between 2000 and 2019, age-standardized diabetes mortality rates increased by 3%. Diabetes-related mortality has increased by 13% in low- and middle-income nations. Moreover, according to an article published by the American Academy of Orthopedic Surgeons, obesity is usually associated with soft tissue injury and osteoarthritis, a degenerative wear and tear condition of the joints. Obesity has a significant impact on osteoarthritis of the hip and knee joints. Every pound of human weight applies four to six pounds of pressure on each knee joint. Obese people are 20 times more likely to require a knee replacement than those who are not overweight. These factors are further contributing to the orthopedic soft tissue repair market share.

Technological Advancements

Technological advancements play a crucial role in driving the growth of the orthopedic soft tissue repair market. These advancements contribute to the development of more effective and less invasive treatment options, enhancing patient outcomes and reducing recovery times. Moreover, technological innovations have led to the development of minimally invasive surgical techniques, such as arthroscopy and laparoscopy, which reduce trauma to surrounding tissues, minimize scarring, and accelerate recovery times compared to traditional open surgeries. For instance, in July 2023, Smith+Nephew, the worldwide medical technology business, launched REGENETEN bioinductive implant in India. The REGENETEN implant has transformed the way surgeons approach rotator cuff surgeries, with over 100,000 procedures conducted globally since its inception. The collagen-based REGENETEN bioinductive implant stimulated the body's natural healing response, allowing the development of new tendon-like tissue to naturally enhance the current tendon and alter disease progression. The implant, roughly the size of a postage stamp is delivered arthroscopically through a small incision over the region of the rotator cuff tendon injury. Apart from this, various developments by the key players are also enhancing the demand for tissue repair. For example, in August 2021, Orthopaedic Implant Company introduced its FDA-cleared DRPX wrist fracture plate, which features type II anodized titanium and a low-profile plate and screw design to reduce soft tissue impingement. These factors are positively influencing the orthopedic soft tissue repair market forecast.

Orthopedic Soft Tissue Repair Industry Segmentation:

Breakup by Procedure:

  • Cruciate Ligaments Repair
  • Rotator Cuff Repair
  • Lateral Epicondylitis
  • Achilles Tendinosis Repair
  • Pelvic Organ Prolapse
  • Gluteal Tendon Repair
  • Hip Arthroscopy
  • Biceps Tenodesis
  • Others

According to the orthopedic soft tissue repair market outlook, cruciate ligaments repair is commonly performed to reconstruct a torn anterior cruciate ligament (ACL) in the knee, which often occurs during sports injuries. Demand for this procedure tends to be consistent due to the prevalence of sports-related injuries. While rotator cuff repair is a group of muscles and tendons that stabilize the shoulder joint. Tears in the rotator cuff are common, especially among older adults and athletes engaged in overhead activities. The demand for rotator cuff repair remains steady due to the aging population and continued participation in sports. Moreover, lateral epicondylitis, commonly known as tennis elbow, is inflammation of the tendons that join the forearm muscles on the outside of the elbow. Treatment options include conservative measures like rest, physical therapy, and corticosteroid injections, but in some cases, surgical intervention may be necessary.

Breakup by Injury Location:

  • Knee
  • Shoulder
  • Hip
  • Small Joints

According to the orthopedic soft tissue repair market outlook, the demand for soft tissue repair procedures in the knee, shoulder, hip, and small joints can vary based on several factors, including the prevalence of injuries, demographic trends, advancements in surgical techniques, and changes in patient preferences. There has been a noted increase in the incidence of ACL knee tears, especially among young athletes participating in high-impact sports like soccer, basketball, and football. Factors contributing to this rise may include increased sports participation, year-round training, and higher intensity levels. Moreover, there has been a rise in rotator cuff injuries in the shoulder, particularly among individuals over 40, possibly due to aging demographics, increased sports participation among older adults, and occupational demands.

Breakup by End User:

  • Hospitals
  • Ambulatory Centers
  • Orthopedic Clinics

Hospitals often handle acute soft tissue injuries requiring immediate attention, such as traumatic ligament tears, tendon ruptures, or severe joint dislocations. Soft tissue repair procedures performed in hospitals may include complex surgeries or revisions. Hospitals can accommodate patients requiring overnight stays or post-operative monitoring, which may be necessary for certain soft tissue repair procedures with extended recovery periods or higher risk profiles. Moreover, ASCs are increasingly popular for performing elective soft tissue repair procedures that do not require overnight hospitalization, such as arthroscopic surgeries for meniscal tears or rotator cuff repairs. Apart from this, orthopedic clinics focus exclusively on musculoskeletal conditions and surgeries, including soft tissue repair procedures. Patients seeking specialized orthopedic care may prefer these clinics for comprehensive evaluations, treatment planning, and post-operative rehabilitation.

Breakup by Region:

  • North America
    • United States
    • Canada
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa

The market research report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa.

According to the orthopedic soft tissue market statistics, the North America region, including the United States and Canada, has well-established medical systems with high levels of healthcare expenditure. Factors such as a large aging population, increasing sports participation, and advancements in medical technology drive the demand for orthopedic soft tissue repair procedures. Moreover, in Europe, countries like Germany, France, and the United Kingdom, have sophisticated healthcare infrastructure and high demand for orthopedic procedures. Additionally, the orthopedic soft tissue repair market in the Asia Pacific region is rapidly expanding due to urbanization, the aging population, and increasing healthcare expenditures. The government's healthcare reforms and investments in medical infrastructure further boost the market growth.

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players that are:

  • Arthrex Inc.
  • Becton Dickinson and Company
  • Boston Scientific Corporation
  • CONMED Corporation
  • Integra LifeSciences
  • Johnson & Johnson
  • LifeNet Health
  • MTF Biologics
  • Smith & Nephew plc
  • Stryker Corporation
  • Tissue Regenix Group plc
  • Zimmer Biomet

Key Questions Answered in This Report

  • 1.How big is the orthopedic soft tissue repair market?
  • 2.What is the future outlook of orthopedic soft tissue repair market?
  • 3.What are the key factors driving the orthopedic soft tissue repair market?
  • 4.Which region accounts for the largest orthopedic soft tissue repair market share?
  • 5.Which are the leading companies in the global orthopedic soft tissue repair market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Orthopedic Soft Tissue Repair Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Procedure

  • 6.1 Cruciate Ligaments Repair
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Rotator Cuff Repair
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Lateral Epicondylitis
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Achilles Tendinosis Repair
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast
  • 6.5 Pelvic Organ Prolapse
    • 6.5.1 Market Trends
    • 6.5.2 Market Forecast
  • 6.6 Gluteal Tendon Repair
    • 6.6.1 Market Trends
    • 6.6.2 Market Forecast
  • 6.7 Hip Arthroscopy
    • 6.7.1 Market Trends
    • 6.7.2 Market Forecast
  • 6.8 Biceps Tenodesis
    • 6.8.1 Market Trends
    • 6.8.2 Market Forecast
  • 6.9 Others
    • 6.9.1 Market Trends
    • 6.9.2 Market Forecast

7 Market Breakup by Injury Location

  • 7.1 Knee
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Shoulder
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Hip
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Small Joints
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast

8 Market Breakup by End User

  • 8.1 Hospitals
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Ambulatory Centers
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Orthopedic Clinics
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia-Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 SWOT Analysis

  • 10.1 Overview
  • 10.2 Strengths
  • 10.3 Weaknesses
  • 10.4 Opportunities
  • 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 Arthrex Inc.
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
      • 14.3.1.3 SWOT Analysis
    • 14.3.2 Becton Dickinson and Company
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
      • 14.3.2.3 Financials
      • 14.3.2.4 SWOT Analysis
    • 14.3.3 Boston Scientific Corporation
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
      • 14.3.3.3 Financials
    • 14.3.4 CONMED Corporation
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
      • 14.3.4.3 Financials
      • 14.3.4.4 SWOT Analysis
    • 14.3.5 Integra LifeSciences
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
      • 14.3.5.3 Financials
      • 14.3.5.4 SWOT Analysis
    • 14.3.6 Johnson & Johnson
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
      • 14.3.6.3 Financials
      • 14.3.6.4 SWOT Analysis
    • 14.3.7 LifeNet Health
      • 14.3.7.1 Company Overview
      • 14.3.7.2 Product Portfolio
    • 14.3.8 MTF Biologics
      • 14.3.8.1 Company Overview
      • 14.3.8.2 Product Portfolio
    • 14.3.9 Smith & Nephew plc
      • 14.3.9.1 Company Overview
      • 14.3.9.2 Product Portfolio
      • 14.3.9.3 Financials
    • 14.3.10 Stryker Corporation
      • 14.3.10.1 Company Overview
      • 14.3.10.2 Product Portfolio
      • 14.3.10.3 Financials
      • 14.3.10.4 SWOT Analysis
    • 14.3.11 Tissue Regenix Group plc
      • 14.3.11.1 Company Overview
      • 14.3.11.2 Product Portfolio
      • 14.3.11.3 Financials
    • 14.3.12 Zimmer Biomet
      • 14.3.12.1 Company Overview
      • 14.3.12.2 Product Portfolio
      • 14.3.12.3 Financials
      • 14.3.12.4 SWOT Analysis
»ùÇà ¿äû ¸ñ·Ï
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
¸ñ·Ï º¸±â
Àüü»èÁ¦